Letter to the Editor
Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease

https://doi.org/10.1016/j.parkreldis.2013.05.002Get rights and content

Section snippets

Acknowledgements

None.

References (5)

There are more references available in the full text version of this article.

Cited by (17)

  • An overview of pain in Parkinson's disease

    2020, Clinical Parkinsonism and Related Disorders
    Citation Excerpt :

    Patients with PD have a high prevalence of symmetrical neuropathy, predominantly in sensory axons [36]. The risk of polyneuropathy has been reported to be increased in patients taking high doses of levodopa [37,38]. Kaur et al. described a patient with pre-existing polyneuropathy that developed acute neuropathic pain, related to a treatment of levodopa-carbidopa intestinal gel (LCIG) infusion [39].

  • Peripheral neuropathy in idiopathic Parkinson's disease: A systematic review

    2017, Journal of the Neurological Sciences
    Citation Excerpt :

    Inflammatory infiltrates of CD8-immunoreactive T-cells were absent [29]. Evidence of inflammatory changes (perivascular lymphocytic cuffing) had been found in sural nerve biopsies in one of 3 patients reported by Kimber et al. [30] when mild inflammatory infiltration lymphocytes in one out of 2 patients reported by Cáceres-Redondo et al. [31]. Vital et al. conducted a pathological study of peripheral nerves from patients with PN and demonstrated intra-axonal ubiquitin aggregates were more numerous in the patients with PN and PD compared to patients without PD [32].

  • Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition

    2016, Parkinsonism and Related Disorders
    Citation Excerpt :

    Electrophysiologic data, TNSr, UPDRS III and UPDRS item 30 scores are reported in Table 2. Several studies reported the frequent occurrence of PN during long-term LD treatment [1–6]. In 2013 our previous large multicenter study, conducted on about 500 pts, we stratified the risk of neuropathy based on the length of LD exposure showing a significant PN prevalence in patients taking LD for a longer period (almost 20% in patients with LD exposure > 3 years); neuropathy was also associated with the cumulative dose of LD, high Hcy and reduced VB12 serum levels [4].

  • Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies

    2014, Parkinsonism and Related Disorders
    Citation Excerpt :

    Whilst long term follow-up studies confirmed CLDII efficacy in controlling motor symptoms, in 2007 the first case of acute PN during CLDII was reported [49] (Table 2). In the following years, along with the increase in CLDII use, there have been other reports of acute/subacute PN, inconstantly associated with signs of encephalopathy [42–46] (Table 2). Some of these acute conditions were associated with severe weight loss and low micronutrients blood levels (vitamin B1, B6, B12, and folate) and improved after CLDII withdrawal with switch back to oral therapy and vitamin supplementation [35,42,50–52].

View all citing articles on Scopus
View full text